Abstract 2084P
Background
CV mortality is the leading preventable cause of death in cancer patients. Understanding the timing and quantifying the magnitude of CV mortality can facilitate strategies to reduce mortality.
Methods
Surveillance, Epidemiology, and End Results (SEER) database (2004-2018) were queried to obtain CV mortality (defined as deaths due to heart diseases, hypertension, cerebrovascular diseases, atherosclerosis, aortic aneurysm, and dissection) in metastatic cancer patients. Standardized mortality ratios (SMRs) were calculated (observed deaths from each category divided by the expected number of deaths in the age-matched US population for the same period). SMR was presented by latency periods of <2, 2-5, and >5 years after the initial diagnosis of metastatic cancer and stratified by age (<50 years, 50-70 years, >70 years), race (White, Black, Asian/Pacific Islander, Native American), and ethnicity (Hispanic, Non-Hispanic).
Results
This analysis included 914,804 metastatic cancer patients. Overall, the risk of CV death was highest <2 years of initial diagnosis (SMR: 2.47, 95% CI: 2.35-2.58) compared to population who died 2-5 years (1.22, 1.17-1.27) and 5>years (1.11, 1.03-1.17) after the initial diagnosis. In terms of different subgroups, younger population (age <50 years) observed the highest risk of CV mortality within < 2 years (8.84, 7.5-10.4) except for prostate cancer, where the risk of cardiovascular death becomes highest at >5 years after diagnosis. Similarly, regarding race, Native Americans had the highest risk of CV mortality (6.44, 4.86-8.54), which remained consistent across different cancers. There was significant increase in observed mortality in Hispanic (2.93, 2.62-3.28) and Non-Hispanic (2.43, 2.31-2.55) population. The mortality risk by ethnicity remained consistent with latency periods of <2, 2-5, and > 5years after the initial diagnosis of metastatic cancer.
Conclusions
Metastatic cancer patients who are younger or those who are Native Americans have the highest CV mortality, especially <2 years of initial diagnosis of metastatic disease. Targeted cardio-oncological strategies should be aimed at improving CV mortality in patients who are at highest risk of deaths.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
I.B. Riaz.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
2028TiP - Phase I, non-randomised, open-label, multi-centre dose escalation trial of BI 764532 (DLL3/CD3 IgG-like T cell engager [TcE]) + ezabenlimab (anti-PD-1 antibody) in patients (pts) with small cell lung cancer (SCLC) and other neuroendocrine carcinomas (NECs) expressing DLL3
Presenter: Julien Mazieres
Session: Poster session 06
2029TiP - Phase I study of ABBV-706, an anti-SEZ6 antibody-drug conjugate, alone or in combination in adults with advanced solid tumors
Presenter: Sreenivasa Chandana
Session: Poster session 06
2035P - Routine biomarker monitoring does not replace comprehensive clinical assessment in the detection of immunotherapy induced myocarditis
Presenter: Alexandra Johnson
Session: Poster session 06
2036P - Prevalence and risk evaluation of cardiovascular disease among newly diagnosed prostate cancer population in China
Presenter: Weiyu Zhang
Session: Poster session 06
2037P - Prehabilitation as a strategy to improve postoperative outcomes in frail cancer patients undergoing elective surgery: A systematic review and meta-analysis
Presenter: Muhammed Elfaituri
Session: Poster session 06
2039P - Primary endpoints of confirmatory randomized controlled trials for older patients with cancer: A scoping review
Presenter: Tomonori Mizutani
Session: Poster session 06
2041P - The prevalence of hematologic adverse events (HAEs) and myelodysplastic syndrome/acute myeloid leukemia (MDS/AML) in patients (pts) with advanced high grade ovarian carcinoma (aHGOC) receiving PARP inhibitor (PARPi), with or without a germline BRCA pathogenic variant
Presenter: Carmine Valenza
Session: Poster session 06
2042P - Improving breast cancer outcomes for indigenous women
Presenter: Vita Christie
Session: Poster session 06
2043P - Can Charlson Comorbidity Index (CCI) and Clinical Frailty Scale (CFS) assessments predict survival in octogenarians with colorectal cancer?
Presenter: Neda Nikolic
Session: Poster session 06
2044P - Bloodstream infections (BSI) in cancer patients: Epidemiology, antibiotic therapy and risk factors related to mortality
Presenter: Carlos López Jiménez
Session: Poster session 06